GR 1014
Alternative Names: GR-1014Latest Information Update: 07 Aug 2024
Price :
$50 *
At a glance
- Originator Suzhou GeneQuantum Healthcare
- Class Antibodies; Drug conjugates; Immunoconjugates
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes
Highest Development Phases
- Phase II Radiodermatitis
Most Recent Events
- 18 Jan 2024 Phase-II clinical trials in Radiodermatitis in China (Topical) (ISRCTN61697120; EudraCT2023-508728-36-00)
- 06 Dec 2021 GR 1014 is available for licensing as of 06 Dec 2021. http://www.genequantum.com/#/common/research?pid=6&id=7&type=5
- 06 Dec 2021 Early research in Unspecified in China (unspecified route) (Suzhou GeneQuantum Healthcare pipeline, December 2021)